As the market awaits first data from a phase II trial in non-Hodgkin's lymphoma (NHL) around the middle of next year, Epizyme Inc. disclosed results showing that none of three patients with synovial sarcoma in the phase I trial with first-in-class EZH2 inhibitor tazemetostat showed a clinical response, but the firm is continuing with a phase II experiment in such patients as well.